Navigation Links
Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
Date:11/15/2010

harmaceuticals Inc. (OTCBB: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, presented the results of its recently completed Phase IIb trial. The multicenter, placebo-controlled, randomized, double-blind study conducted in 29 patients with Type II diabetes assessed the safety of ORMD-0801 in patients with Type II diabetes. Results were presented by the company's Chief Scientific Officer, Dr. Miriam Kidron, at the Tenth Annual Meeting of the Diabetes Technology Society, in Bethesda, Maryland.

The poster presentation entitled "Extended exposure to an oral insulin formulation yields decreased insulin secretion in Type II diabetes subjects," described Oramed's first extended exposure study to its oral insulin product (ORMD-0801), where 21 patients were treated with ORMD-0801, self-administered daily for a period of six weeks. In parallel, a group of eight patients received placebo capsules administered under the same treatment regimen. ORMD-0801 proved safe and tolerable, with no reports of serious adverse events throughout the study. In addition, no cumulative effects of extended ORMD-0801 exposure were noted, and only two mild cases of transient hypoglycemia were reported. Treatment efficacy was evaluated via markers quantified from blood samples drawn at the start and end of the study. Daily administration of oral insulin led to a statistically significant decrease in both insulin and C-reactive protein (CRP) levels, in contrast to their elevation among placebo-treated individuals. Moreover, the percentage of subjects demonstrating clinically relevant reductions in insulin, c-peptide, fasting blood glucose (FBG) and Hb1Ac levels was consistently higher in the ORMD-0801 cohort, when compared to its placebo counterpart. This study addressing, for the first time, potential long-term safety concerns from extended ORMD-0801 administrations, demonstrated safety and no seri
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010
2. Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism
3. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
4. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
5. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
6. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
7. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
8. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
9. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
10. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
11. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
(Date:12/19/2014)... Charm Sciences is pleased to announce ... of Aflatoxin M1 in raw commingled milk is the ... validation. The peer reviewed report of the validation by ... Agricultural and Fisheries Research (ILVO-T&V) has been published by ... the most toxic aflatoxin and a known carcinogen, can ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 BioPlus ... specialty pharmacies, announces the promotion of Nick Maroulis, Pharm.D. ... Specialty Pharmacy Services. , In this position, Dr. ... while also managing the directors of our multi-site pharmacies ... BioPlus since 1997 and during that time he has ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... - Leslie Hearn's first rule for the execution of ... techno jargon is unavoidable, the value of plain-spoken communication is ... Telecom . , , Leslie Hearn "Great ... said. "There has to be a lot of plain talk ...
... Wis. - aOva Technologies , a developer of ... nest egg. , ,aOva recently announced the closing of ... closed one week ahead of schedule. The funding, collected from ... further its line of antibody egg products that improve feed ...
... Darwin Smith may or may not have brought down a ... 1983, and Wisconsin had just elected liberal Democrat Tony Earl ... an income tax increase, and Smith issued a dire warning ... climate. , ,Two years later, Smith moved Kimberly-Clark's corporate headquarters ...
Cached Biology Technology:CIO Leadership Series: Leslie Hearn, TDS Telecom 2CIO Leadership Series: Leslie Hearn, TDS Telecom 3CIO Leadership Series: Leslie Hearn, TDS Telecom 4aOva Technologies raises $3 million 2RedPrairie: Will they stay, or will they go? 2RedPrairie: Will they stay, or will they go? 3RedPrairie: Will they stay, or will they go? 4
(Date:12/19/2014)... 18, 2014 Research and Markets ... the "iPhone 5S Fingerprint Sensor - Apple/AuthenTec ... to their offering. ... AuthenTec in July 2012, Apple introduced the fingerprint ... currently the only device of Apple incorporating such ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) ... Monitor: North America Perimeter Security Systems Market" report ... The North American perimeter security market ... from 2014 to 2019. Although the U.S. market holds ... is expected to grow at a higher ...
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the ... a study that pinpoints fine-scale differences in genetic ancestry ... . Since immigrants first arrived more ... States has served as a meeting place ... American history and the ongoing mixing of peoples with ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 323andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... total stock of fish on the planet had been reckoned ... of them were thought to be mesopelagic fish, in other ... metres in ocean areas. However, an international team*, in ... by the doctor in oceanography Xabier Irigoien, has discovered that ...
... sites that generates the most scientific debate is the dating ... at the Spanish National Research Centre for Human Evolution, among ... the , Journal of Archaeological Science , has clarified that ... Homo antecessor were discovered in 1994, is 900,000 ...
... honey producer and fifth largest honey exporter in the ... in Mexico to quantify the genetically modified organism (GMO) ... Germany. Their results will appear Feb. 7 in the ... staff scientist at the Smithsonian Tropical Research Institute, and ...
Cached Biology News:Dating is refined for the Atapuerca site where Homo antecessor appeared 2Smithsonian reports GMO soybean pollen threatens Mexican honey sales 2
...
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Goat polyclonal to Duffy / FY / DARC...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: